{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-252054","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.560650+00:00","generated_at":"2026-05-30T04:28:22.565407+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Soleno Therapeutics Q3 net loss $76.6M; NDA for DCCR in PWS accepted with Priority Review, PDUFA Dec 27, 2024","bullets":["NDA for DCCR (diazoxide choline) for Prader-Willi syndrome accepted by FDA with Priority Review; PDUFA target action date December 27, 2024.","Net loss $76.6M ($1.83/sh) vs $10.9M ($0.95/sh) in Q3 2023; increase driven by non-cash stock-based compensation tied to NDA milestones.","R&D expense $30.1M (includes $18.5M stock comp); G&A expense $49.2M (includes $38.1M stock comp), both up significantly from prior year.","Cash, cash equivalents and marketable securities $284.7M as of Sept 30, 2024; cash used in operations $14.9M in Q3.","Board appointed Dawn Carter Bir and Matthew Pauls assumed Lead Independent Director role."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-252054","json":"https://secwatch.observer/filing/0001193125-24-252054.json","markdown":"https://secwatch.observer/filing/0001193125-24-252054.md","text":"https://secwatch.observer/filing/0001193125-24-252054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312524252054/0001193125-24-252054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312524252054/d889134d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:28:22.565407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}